Biodegradable polymeric iodine contrast agents for CT angiography.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL117473-01
Agency Tracking Number: R43HL117473
Amount: $237,184.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NHLBI
Solicitation Number: PA12-088
Small Business Information
DUNS: 784163446
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (631) 205-1682
Business Contact
Phone: (631) 205-9490
Research Institution
DESCRIPTION (provided by applicant): Recent advances in micro-CT machines have made it possible to image with a resolution of lt10 m. Scans take ~6 to 20 minutes to acquire, and current iodine contrast agents due to their short half-lives are not generally suitable. We recentl commercialized non-toxic gold X-ray contrast agent, AuroVist , but they are lot more expensive than iodine agents and their whole body clearance is very slow. We now propose biodegradable polymeric contrast agents that are composed of FDA approved components: hyaluronic acid or polylactide/polyglycolide and a derivative of iodine agent Iobitridol that are lot cheaper than our gold-based contrast agents and more absorptive than conventional iodine agents. The new agents can be labeledwith additional contrast agents, such as gadolinium or iron oxide, enabling multimodal imaging or double contrasting with dual-beam/dual-detector CT. When labeled with iodine agents and targeting molecules will enable in vivo visualization of organ function, angiogenesis, repair, tumor formation, metastasis, studies of response to drugs and other therapies or conditions, such as ischemia or radiation, and basic biological studies of animals including development, infection, immune response, cardiac studies, tissue injury and healing. The new contrast agents will provide more than four times the radiodensity as compared to the conventional iodine contrast agents and will enable longer imaging times as they are intravascular. These agents will more accurately identify vulnerable plaque by clearly identifying lipid core volume as a percentage of plaque volume, angiogenesis/inflammation, and stenoses, among other risk factors. In addition, their higher radiodensity will enable better imaging of obese patients,reduce radiation dose in normal sized patients and reduce nephrotoxicity to permit use in kidney compromised patients. These capabilities go beyond what other agents offer and if clinically implemented could, through screening, reduce the prevalence of coronary artery disease deaths. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposed novel biodegradable polymeric contrast agents for computed tomography will provide higher contrast than conventional iodine agents, reduce X-ray doses tomillions of patents, and when used with gadolinium agents will enable multimodal imaging and double contrasting.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government